MedTrace Logo

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

NCT02601001 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-07-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of omecamtiv mecarbil in healthy volunteers in Japan.

Conditions

  • Healthy Volunteer

Interventions

DRUG

Omecamtiv mecarbil

Omecamtiv mecarbil tablets for oral administration

DRUG

Placebo

Matching placebo tablets

Sponsors & Collaborators

  • Cytokinetics

    lead INDUSTRY

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-13
Primary Completion
2016-01-06
Completion
2016-01-06

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02601001 on ClinicalTrials.gov